These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 18166813)

  • 1. Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal.
    Ronchi CL; Rizzo E; Lania AG; Pivonello R; Grottoli S; Colao A; Ghigo E; Spada A; Arosio M; Beck-Peccoz P
    Eur J Endocrinol; 2008 Jan; 158(1):19-25. PubMed ID: 18166813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors.
    Ronchi CL; Varca V; Beck-Peccoz P; Orsi E; Donadio F; Baccarelli A; Giavoli C; Ferrante E; Lania A; Spada A; Arosio M
    J Clin Endocrinol Metab; 2006 Jan; 91(1):121-8. PubMed ID: 16263816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuation of somatostatin analogs while acromegaly is in long-term remission.
    Hatipoglu E; Bozcan S; Kadioglu P
    Pituitary; 2015 Aug; 18(4):554-60. PubMed ID: 25301076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can we predict long-term remission after somatostatin analog withdrawal in patients with acromegaly? Results from a multicenter prospective trial.
    Vilar L; Fleseriu M; Naves LA; Albuquerque JL; Gadelha PS; dos Santos Faria M; Nascimento GC; Montenegro RM; Montenegro RM
    Endocrine; 2014 Aug; 46(3):577-84. PubMed ID: 24272601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GH/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide.
    Attanasio R; Barausse M; Cozzi R
    J Endocrinol Invest; 2001 Apr; 24(4):209-16. PubMed ID: 11383906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly.
    Cozzi R; Dallabonzana D; Attanasio R; Barausse M; Oppizzi G
    Eur J Endocrinol; 1999 Sep; 141(3):267-71. PubMed ID: 10474124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of biochemical control of acromegaly during treatment with somatostatin analogues by oral glucose load and insulin-like growth factor I.
    Scacchi M; Carzaniga C; Vitale G; Fatti LM; Pecori Giraldi F; Andrioli M; Cattaneo A; Cavagnini F
    J Endocrinol Invest; 2011 Oct; 34(9):e291-5. PubMed ID: 21697649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa.
    Maiza JC; Vezzosi D; Matta M; Donadille F; Loubes-Lacroix F; Cournot M; Bennet A; Caron P
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):282-9. PubMed ID: 17524029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience.
    Sala E; Carosi G; Del Sindaco G; Mungari R; Cremaschi A; Serban AL; Ronchi CL; Ferrante E; Arosio M; Mantovani G
    J Endocrinol Invest; 2021 Dec; 44(12):2593-2599. PubMed ID: 34018167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly.
    Ayuk J; Stewart SE; Stewart PM; Sheppard MC
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4142-6. PubMed ID: 12213862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg).
    Baldelli R; Colao A; Razzore P; Jaffrain-Rea ML; Marzullo P; Ciccarelli E; Ferretti E; Ferone D; Gaia D; Camanni F; Lombardi G; Tamburrano G
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4099-103. PubMed ID: 11095439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly.
    Schmid HA; Brue T; Colao A; Gadelha MR; Shimon I; Kapur K; Pedroncelli AM; Fleseriu M
    Endocrine; 2016 Jul; 53(1):210-9. PubMed ID: 26906713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adequacy of current postglucose GH nadir limit (< 1 microg/l) to define long-lasting remission of acromegalic disease.
    Ronchi CL; Arosio M; Rizzo E; Lania AG; Beck-Peccoz P; Spada A
    Clin Endocrinol (Oxf); 2007 Apr; 66(4):538-42. PubMed ID: 17371472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
    Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A
    Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly.
    Cardinal T; Rutkowski MJ; Micko A; Shiroishi M; Jason Liu CS; Wrobel B; Carmichael J; Zada G
    Neurosurg Focus; 2020 Jun; 48(6):E10. PubMed ID: 32480366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide.
    Suliman M; Jenkins R; Ross R; Powell T; Battersby R; Cullen DR
    J Endocrinol Invest; 1999 Jun; 22(6):409-18. PubMed ID: 10435849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effect of 6 Months' Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings.
    Witek P; Bolanowski M; Szamotulska K; Wojciechowska-Luźniak A; Jawiarczyk-Przybyłowska A; Kałużny M
    Front Endocrinol (Lausanne); 2021; 12():633944. PubMed ID: 33776927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of two different somatostatin analogs on glucose tolerance in acromegaly.
    Ronchi C; Epaminonda P; Cappiello V; Beck-Peccoz P; Arosio M
    J Endocrinol Invest; 2002 Jun; 25(6):502-7. PubMed ID: 12109620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
    Colao A; Pivonello R; Cappabianca P; Briganti F; Tortora F; Auriemma RS; De Martino MC; Marzullo P; Lombardi G
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.
    Petersenn S; Schopohl J; Barkan A; Mohideen P; Colao A; Abs R; Buchelt A; Ho YY; Hu K; Farrall AJ; Melmed S; Biller BM;
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2781-9. PubMed ID: 20410233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.